Endothelial dysfunction and diabetes: Fundamental aspects and therapeutic perspectives;Dysfonctionnement endothélial et diabète: Aspects fondamentaux et perspectives thérapeutiques

Angeiologie

Volumn 55, Issue 2, 2003, Pages 33-40

  Hillaire Buys, D ^a,b   Peyriere, H ^b   Linck, N ^a   Saiag B ^c  

^a Lab Biopathol Nerveuse Musculaire   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c ERCS Sciences du Sport   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; ENDOTHELIN 1; GLUCOSE; NITRIC OXIDE;

ANGIOGENESIS; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; CELL MEMBRANE PERMEABILITY; DETOXIFICATION; DIABETES MELLITUS; DYSLIPIDEMIA; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; NONHUMAN; REVIEW; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 9644288792     PISSN: 00033049     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. DESPRES J.P., BENOIT LAMARCHE PH. D., SC. M., MAURIEGE P., D. PH., CANTIN B., D.M., DAGENAIS GILLES R., D.M., MOORJANI SITAL, D. PH., LUPIEN P.J., D.M.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. The New England Journal of Medicine. 1996 April. 334 n°15: 952-957.
2. ESCHWEGE E., CHARLES M.A., BALKAU B.: Glycemic, insulinemie, insulino-résistance: épidémiologie du risque cardiovasculaire. Act. Med. Int. Août 2000. 4: 152-156.
3. MAYAUDON H., O. DUPUY, L. BORDIER, B. BAUDUCEAU: - Risque cardiovasculaire absolu chez le diabétique. La Presse Médicale. 9 septembre 2000. 29 n°25. 1397-1400.
4. CHAMONTIN B., M. MARRE: Insulinorésistance, hypertension artérielle et prévention cardiovasculaire: implications thérapeutiques. La Presse Médicale. 26 avril 1997. 26 n°14. 671-677.
5. RUBANYI GABOR M.: Endothelium Derived Relaxing and Contracting Factors. Journal of Cellular Biochemistry. 1991. 46: 27-36.
6. HALIMI J.M., Y. LEBRANCHU: Régulation et dysfonctionnement de la vasomotricité dépendant de l'endothélium: que faut-il en retenir pour la pratique? La Presse Médicale. 9 décembre 2000. 29. 2109-2115.
7. LUSCHER F., THOMAS, M.D., MATTHIAS BARTON, M.D.: Biology of the endothelium. Clin. Cardiol. 1997.Vol. 20 (Suppl. II), II-3/II-10.
8. GOODFELLOW J., RAMSEY M.W., LUDDINGTON L.A., JONES C.J.H., COATES P.A., DUNSTAN F., LEWIS M.J., OWENS D.R., HENDERSON A.H.: Endothelium and inelastic arteries: an early marker of vascular dysfunction in non insulin dependent diabetes. BMJ, 1996; 312: 744-5.
9. SOBREVIA L., G.E. MANN: Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia. Experimental Physiology. 1997; 82: 423-452.
10. RODRIGUEZ-MANAS LEOCADION, JAVIER ANGULO, CONCEPCION PEIRO, JOSE L. LLERGO, ALBERTO SANCHEZ-FERRER, PEDRO LOPEZ-DORIGA, CARLOS R SANCHEZ-FERRER: Endothelial dysfunction and metabolic control in streptozotocin-induced diabetic rats. British Journal of Pharmacology. 1998; 123: 1495-1502.
11. GOPAUL N.K., M.D. MANRAJ, A. HEBE, S. LEE KWAI YAN, A. JOHNSTON, M.J. CARRIER, E.E. ANGGARD: Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian mauritians with impaired glucose metabolism. Diabetologia. 2001; 44: 706-712.
12. CRACOWSKI J.L., F. STANKE-LABESQUE, C. SOUVIGNET, G. BESSARD: Isoprostanes: nouveaux marqueurs du stress oxydant en pathologie humaine. La Presse Médicale. 25 mars 2000; 29: 604-610.
13. O'BYRNE Sharon, PABLO FORTE, L. JACKSON ROBERTS II, JASON D., MORROW, ATHOLL JOHNSTON, ERIC ANGGARD, R.D.G. LESLIE, NIGEL BENJAMIN: Nitric oxide synthesis nd isoprostane production in subjects with type 1 diabetes and normal urinary albumin excretion. Diabetes. May 2000; 49: 857-862.
14. NEUGEBAUER S., TSUNEHARU B., TSUYOSHI W.: Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes. March 2000. 49. 500-503.
15. XIAN-JIE Y., YUAN-JIAN LI, VAN XIONG: Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sciences. 1994; 54 n°12: 753-758.
16. MITTERMAYER F., MAYER B.X., MEYER A., WINZER C., PACINI G., WAGNER O.F., WOLZT M., KAUTSKY-WILLER A.: Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with previous gestational diabetes. Diabetologia. 2002 Oct. 45(10): 1372-8.
17. ITO A., EGASHIRA K., NARISHIGE T., MURAMATSU K., TAKESHITA A.: Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ. J. 2002 Sept. 66(9): 811-5.
18. ASAGAMI T., ABBASI F., STUELINGER M., LAMENDOLA C., MCLAUGHLIN T., COOKE J.P., REAVEN G.M., TSAO P.S.: Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 2002 Jul. 51(7): 843-6.
19. BARON A.D., ZHU J.S., MARSHALL S., IRSULA O., BRECHTEL G., KEECH C.: Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor 1-NMMA in rats. Am. J. Physiol. 269: E709-E715. 1995.
20. SHANKAR R., ZHU J.S., LADD B., HENRY D., SHEN H.Q., BARON A.D.: central nervous system nitric oxide synthase activity regulates insulin secretion and insulin action. J. Clin. Invest. 102: 1403-1412. 1998.
21. SHANKAR R., YONGANG WU, HUA-QIONG SHEN, JIN-SU ZHU, BARON A.D.: Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes. May 2000. 49: 684-687.
22. COOKE C.L., DAVIDGE S.T.: Peroxynitrite increases Inos through NF-KappaB and decreases prostacyclin synthase in endothelial cells. Am. J. Physiol. 2002 Feb. 282(2): C395-402.
23. HISHINUMA T., TSUKAMOTO H., SUZUKI K., MIZUGAKI M.: Relationship between thromboxane / prostacyclin ratio and diabetic vascular complications. Prostaglandins Leukot Essent Fatty Acids. 2001 Oct. 65(4): 191-6.
24. ZOU M.H., SHI C., COHEN R.A.: High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane / prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes. 2002 Jan.. 51(1): 198-203.
25. CAMPBELL W.B., GAUTHIER K.M.: What is new in endothelium-derived hyperpolarizing factors? Curr. Opin. Nephrol. Hypertens. 2002 March 11(2): 177-83.
26. JACK A., KEEGAN A., COTTER M., CAMERON N.: Effects of diabetes and evening primrose oil treatment on responses of aorta, corpus cavernosum and mesenteric vasculature in rats. Life Sci. 2002 Sept 6. 71(16): 1863.
27. MINAMI A. ISHIMURA N. HARADA N., SAKAMOTO S., NIWA Y., NAKAYA Y.: Exercice training improves acetylcholine-induced endothelium-depedent hyperpolarization in type 2 diabetic rats, otsuka long-evans tokushima fatty rats. Atherosclerosis. 2002 May: 162(1): 85-92.
28. WIGG S.J., TARE M., TONTA M.A., O'BRIEN R.C., MEREDITH I.T., PARKINGTON H.C.: Comparison of effects of diabetes mellitus on an EDHF-dependent and an EDHF-independent artery. Am. J. Physiol Heart. Circ. Physiol. 2001 Jul. 281(1). H 232-40.
29. DE VRIESE A.S., VAN DE VOORDE J., BLOM H.J., VANHOUTTE P.M., VERBEKE M., LAMEIRE N.H.: The impaired renal vasodilator response attributed to endothelium - derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate. Diabetologia. 2000 Sept. 43(9): 1116-25.
30. ENDO K., ABIRU T., MACHIDA H., KASUYA Y., KAMATA K.: Endothelium-derived hyperpolarizing factor does not contribute to the decrease in endothelium-dependent relaxation in the aorta of streptozotocin-induced diabetic rats. Gen. Pharmacol. 1995 Jan. 26(1): 149-53.
31. DE VRIESE A.S., VERBEUREN T.J., VAN DE VOORDE J., LAMEIRE N.H., VANHOUTTE P.M.: Endothelial dysfunction in diabetes. Br. J. Pharmacol. 2000 Jul. 130(5): 963-74.
32. HILLAIRE-BUYS D., GROSS R., CHAPAL J., RIBES G., LOUBATIERES-MARIANI M.M.: P2y purinoceptor responses of β - cells and vascular bed are preserved in diabetic rat pancreas. Br. J. Pharmacol. 1992. 106: 610-5.
33. SAIAG B., HILLAIRE-BUYS D., CHAPTAL J., PETIT P., PAPE D., RAULT B., ALLAIN H., LOUBATIERES-MARIAM M.M.: Study of the mechanisms involved in adenosine-5′-O-(2-thiodiphosphate) induced relaxation of rat thoracic aorta and pancreatic vascular bed. British Journal of Pharmacology. 1996. 118. 804-810.
34. LAURENT F., HILLAIRE-BUYS D., CHAPAL J., DIETZ S., PORTET K., CROS G., PETIT P., MICHEL A.: Contrasting effects of streptozotocin-induced diabetes on the in vitro relaxant properties of adenosine in rat pancreatic vascular bed and thoracic aorta. Naunyn-Schmiedeberg's Arch Pharmacol. 1999. 360: 309-316.
35. CHIARELLI F., F. CIPOLLONE, F. ROMANO, S. TUMINI, FABRIZIO COSTANTINI, L. DI RICCO, M. POMILIO, S.D. PIERDOMENICO, M. MARINI, F. CUCCURULLO, A. MEZZETTI: Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes. July 2000. 49: 1258-1262.
36. WU G., MEININGER C.J.: Regulation of nitric oxide synthesis by dietary factors. Annu. Rev. Nutr. 2002. 22. 61-86.
37. HOPFNER R.L., GOPALAKRISHNAN V.: Endothelin: emerging role in diabetic vascular complications. Diabetologia. 1999 Dec. 42(12): 1383-1394.
38. MIGDALIS I.N., KALOGEROPOULOU K., KARMANIOLAS K.D., VARVARIGOS N., MORTZOS G., CORDOPATIS P.: Plasma levels of endothelin and early carotid atherosclerosis in diabetic patients. Res. Commun. Mol. Pathol. Pharmacol. 2000 Jul-Aug. 108(1-2): 15-25.
39. MIGDALIS I.N., KALOGEROPOULOU K., ILIOPOULOU V., TRIANTAFILOU P., CHARALABIDES J., MORTZOS G., CORDOPATIS C.: Plasma levels of endothelin, lipid peroxides and prostacyclin in diabetic patients with macroangiopathy. Diabetes Res. Clin. Pract. 2001 Nov. 54(2): 129-36.
40. SARMAN B., FARKAS K., TOTH M., SOMOGYI A., TULASSAY Z.: Circulating plasma endothelin-l plasma lipids and complications in type I diabetes mellitus. Diabetes Nutr. Metab. 2000 Jun. 13(3). 142-8.
41. SELIGMAN B.G., BIOLO A., POLANCZYK C.A., GROSS J.L., CLAUSELL N.: Increased plasma levels of endothelin 1 and von willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2000 Sept. 23(9). 1395-400.
42. MAC AULEY D.F., MAC GURK C., NUGENT A.G., HANRATTY C., HAYES J.R., JOHNSTON G.D.: Vasoconstriction to endothelin-1 is blunted in non-insulin-dependent diabetes: a dose-response study. J. Cardiovasc. Pharmacol. 2000 Aug. 36(2): 203-8.
43. GREGERSEN S., THOMSEN J.L., HERMANSEN K.: Endothelin-1 (Et-1) potentiated insulin secretion: involvement of protein kinase C and the ET(A) receptor subtype. Metabolism. 2000 Feb.. 49(2): 264-9.
44. BROCK B., GERGERSEN S., KRISTENSEN K., THOMSEN J.L., BUSCHARD K., KOFOD H., HERMANSEN K.: the insulinotropic effect of endothelin-1 is mediated by glucagon release from the islet alpha cells. Diabetologia. 1999 Nov. 42(11): 1302-7.
45. MATHER K., ANDERSON T.J., VERMA S.: Insulin action in the vasculature: physiology and pathophysiology. J. Vasc. Res. 2001 Sep-Oct. 38(5): 415-22.
46. BIERHAUS A., HOFMANN M.A., ZIEGLER R., NAWROTH P.P.: The age/rage pathway in vascular disease and diabetes mellitus. Part I. The age-concept. Cardiovasc. Res. 1998. 37: 586-600.
47. HOFMANN M.A., DRURY S., FU C., WU Q., TAGUCHI A., LU Y., AVILA C., KAMBHAM N., SLATTERY T., BEACH D., MAC CLARY J., NAGASHIMA M., MORSER J., BIERHAUS A., NEURATH M., NAWROTH P., STERN D., SCHMIDT A.M.: rage mediates a novel proinflammatory axis: the cell surface receptor for S100/calgranulin polypeptides. Cell. 1999. 97: 889-901.
48. BIERHAUS A., SCHIEKOFER S., SCHWANINGER M., ANDRASSY M., HUMPERT PER M., CHEN JIANG, HONG MEI, LUTHER T., HENLE T., KLOTING I., MORCOS M., HOFMANN M., TRITSCHLER H., WEIGLE B., KASPER M., SMITH M., PERRY G., SCHMIDT A.M., STERN D.M., HARING H.U., SCHLEICHER E., NAWROTH P.P.: Diabetes-associated sustained activation of the transcription factor nuclear factor-kb. Diabetes. December 2001. 50. 2792-2808.
49. QUEHENBERGER P., A. BIERHAUS, P. FASCHING, C. MUELLNER, M. KLEVESATH, M. HONG, G. STIER, M. SATTLER, E. SCHLEICHER, W. SPEISER, PETER P. NAWROTH: Endothelin 1 transcription is controlled by nuclear factor-kb in Age-stimulated cultured endothelial cells. Diabetes. September 2000. 49. 1561-1570.
50. BONNEFONT-ROUSSELOT D.: Antioxidant and anti-Age therapeutics: evaluation and perspectives. J. Soc. Biol. 2001. 195(4): 391-8.
51. PARK SOO, JAE HYEON KIM, MIN SEON KIM, JEONG MI KIM, SUK KYEONG KIM, YUN CHOI, MYUNG HEE CHUNG, BOGHEE HAN, SEONG YEON KIM, HONG KYE LEE: Effects of insulin and antioxidant on plasma 8-hydroxyguanine and tissue 8-hydroxydeoxyguanosine streptozotocin-induced diabetic rats. Diabetes. December 2001. 50. 2837-2841.
52. COPPEY LAWRENCE J., JILL S. GELLETT, ERIC P. DAVIDSON, JOYCE A. DUNLAP, DONALD D. LUND, MARK A. YOREK: Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes. August 2001. 50: 1927-1937.
53. FIJRMM E.B., STAMPFER M.J., ASCHERIO A., GIOVANNUCCI E., COLDITZ G.A., WILLETT W.C.: Vitamin E consumption and the risk of coronary disease in women. N. Engl. J. Med. 328: 1450-1456. 1993.
54. TARDIF J.C., COTE G., LESPERANCE J., BOURASSA M., LAMBERT J., DOUCET S., PILODEAU L., NATTEL S., DE GUISE P.: Probucol Multivitamins in the prevention of restenosis after coronary angioplasty: multivitamins and probucol study group. N. Engl. J. Med. 337: 365-372. 1997.
55. FUJIHARA C.K., MATTAL A.L., VIEIRA J.M., MALHEIROS D.M., NORONHA I.D., IDE L., GONCALVES A.R., DE NUCCI G., ZATZ R.: Evidence for the existence of two distinct functions for the inducible NO synthase in the rat kidney: effect of amino-guanidine in rats with 5/6 ablation. J. Am. Soc. Nephrol. 2002 Sept. 13(9): 2278-87.
56. MIYOSHI H., TAGUCHI T., SUGIURA M., TAKEUCHI M., YANAGISAWA K., WATANABE Y., MIWA I., MAKITA Z., KOIKE T.: Aminoguanidine pyridoxal adduct is superior to amino-guanidine for preventing diabetic nephropathy in mice. Horm. Metab. Res. 2002.: 371-3770.
57. WOLFF D.J., LUBESKIE A.: Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch. Biochem. Biophys. 1995 Jan. 10. 316(1). 290-301.
58. NAKAGAMI H., MORISHITA R., YAMAMOTO K., YOSHIMURA S., TANIYAMA Y., AOKI M., MATSUBARA H., KIM S., KANEDA Y., OGIHARA T.: Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high d-glucose in human endothelial cells. Diabetes. June 2001;50:1472-1481.
59. WASCHER THOMAS C., GERALD WOLKART, JAMES C. RUSSELL, FRIEDRICH BRUNNER: Delayed insulin transport across endothelium in insulin-resistant JCR: LA-cp rats. Diabetes. May 2000;49:803-809.
60. BERTELSEN M., E.E. ANGGARD, M.J. CARRIER: Oxidative stress impairs insulin internalization in endothelial cells in vitro. Diabetologia. 2001. 44: 605-613.
61. BOOTH G., STALKER T.J., LEFER A.M., SCALIA R.: Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin. Am. J. Physiol. Endocrinol. Metab. 2001 Jun. 280(6): E848-56.
62. GHITESCU LUCIAN D., ALEJANDRO GUGLIUCCI, FRANCE DUMAS: Actin and annexins I and II are among the main endothelial plasmalemma-associated proteins forming early glucose adducts in experimental diabetes. Diabetes. July 2001;50:1666-1674.
63. KOWALSKA I., STRACZKOWSKI M., SZELACHOWSKA M., KINALSKA I., PROKOP J., BACHORZEWSKA-GAJEWSKA H., STEPIEN A.: Circulating E-selectin, vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism. Metabolism. 2002 Jun. 51(6): 733-6.
64. MATSUMOTO K., MORISHITA R., TOMITA N., MORIGUCHI A., YAMASAKI K., AOKI M., MATSUMOTO K., NAKAMURA T., HIGAKI J., OGIHARA T.: Impaired endothelial dysfunction in diabetes mellitus rats was restored by oral administration of prostaglandin 12 analogue. J. Endocrinol. 2002 Oct. 175(1): 217-223.
65. MC LAREN M., ELHADD T.A., GREENE S.A., BELCH J.J.: Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin. Appl. Thromb. Hemost. 1999 Jan. 5(1): 21-4.
66. CHIARELLI F., SANTILLI F., MOHN A.: Role of growth factors in the development of diabetic complications. Horm. Res. 2000,53(2): 53-67.
67. JAGER A., VICTOR W.M. VAN HINSBERGH, PIET J. KOSTENSE, JEF J. EMEIS, GIEL NIJPELS, JACQUELINE M. DEKKER, ROBERT J. HEINE, LEX M. BOUTER, COEN D.A.: Stehouwer. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes. Diabetes. March 2000. 49: 485-491.
68. MURATA T., NAGAI R., ISHIBASHI T., INOMUTA H., IKEDA K., HORIUCHI S.: the relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 1997 Jul. 40(7): 764-9.
69. MARSH S., NAKHOUL P.M., SKORECKI K., RUBIN A., MILLER B.P., LEIBU R., LEVY N.S., LEVY A.P.: Hypoxic induction of vascular endothelial growth factor is markedly decreased in diabetic individuals who do not develop retinopathy. Diabetes Care. 2000 Sept. 23(9): 1375-80.
70. BRAUN L., KARDON T., REISZ-PORSZASZ Z.S., BANHEGYI G., MANDL J.: The regulation of the induction of vascular endothelial growth factor at the onset of diabetes in spontaneously diabetic rats. Life Sci. 2001. 69(21). 2533-42.
71. PINTER E., HAIGH J., NAGY A., MAORI J.A.: Hyperglycemia-induced vasculopathy in the murine conceptus is mediated via reductions of VEGF-A expression and VEGF receptor activation. Am. J. Pathol. 2001 Apr. 158(4): 1199-206.
72. DE VRIESE A.S., TILTON R.G., ELGER M., STEPHAN C.C., KRIZ W., LAMEIRE N.H.: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol. 2001 May. 12(5): 993-1000.
73. DE VRIESE A.S., TILTON R.G., STEPHAN C.C., LAMEIRE N.H.: Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J. Am. Soc. Nephrol. 2001 Aug. 12(8): 1734-41.
74. RIVARD A., SILVER M., CHEN D., KEARNEY M., MAGNER M., ANNEX B., PETERS K., ISNER J.M.: Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am. J. Pathol. 1999 Feb. 154(2): 355-63.
75. HAUNER H.: The mode of action of thiazolidinediones. Diabetes Metab. Res. Rev. 2002 Mar-Apr. 18. Suppl 2: S10-5.
76. EMOTO M., T. ANNO, Y. SATO, Y. SATO, K. TANABE, S. OKUYA, Y. TANIZAWA, A. MATSUTANI, Y. OKA: Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes. May 2001. 50: 1166-1170.